RE:RE:New Press Release - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Programso, IF as ONCY claims they have a clear path forward... there is no need to wait for the OS results to be relesed later in the year. They should start authoring the CTA NOW.
and what a surprise, NO accelerated approval for mBC.
This would suggest that FDA has not approved a surrogate end point based on ONCY's potential biomarkers..
the pps tells you everything you need to know... unless there is substantive news. sale/partnership, expect another reverse split to stay listed on Nasdaq.